# Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

> **NCT05294666** · PHASE4 · COMPLETED · sponsor: **Peking University Third Hospital** · enrollment: 89 (actual)

## Conditions studied

- Graft Versus Host Disease in Eye

## Interventions

- **DRUG:** Cyclosporine
- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT05294666
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05294666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05294666, "Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05294666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*